{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T08:28:01Z","timestamp":1767860881504,"version":"3.49.0"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,3,17]],"date-time":"2018-03-17T00:00:00Z","timestamp":1521244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Pfizer Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s40121-018-0196-z","type":"journal-article","created":{"date-parts":[[2018,3,17]],"date-time":"2018-03-17T01:55:57Z","timestamp":1521251757000},"page":"219-234","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["A Review of Meningococcal Disease and Vaccination Recommendations for Travelers"],"prefix":"10.1007","volume":"7","author":[{"given":"Lidia C.","family":"Serra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura J.","family":"York","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amgad","family":"Gamil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Balmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Webber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,3,17]]},"reference":[{"key":"196_CR1","unstructured":"World Tourism Organization. UNWTO tourism highlights, 2016. Available at: http:\/\/www.e-unwto.org\/doi\/pdf\/10.18111\/9789284418145 . Accessed November 2, 2017."},{"issue":"suppl","key":"196_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1708-8305.2010.00451.x","volume":"17","author":"A Wilder-Smith","year":"2010","unstructured":"Wilder-Smith A. Meningococcal disease in travelers: a rare but devastating disease. J Travel Med. 2010;17(suppl):1\u20132.","journal-title":"J Travel Med"},{"issue":"suppl","key":"196_CR3","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.jadohealth.2016.04.012","volume":"59","author":"SI Pelton","year":"2016","unstructured":"Pelton SI. The global evolution of meningococcal epidemiology following the introduction of meningococcal vaccines. J Adolesc Health. 2016;59(suppl):S3\u201311.","journal-title":"J Adolesc Health"},{"key":"196_CR4","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1086\/525260","volume":"46","author":"A Gottberg von","year":"2008","unstructured":"von Gottberg A, du Plessis M, Cohen C, et al. Emergence of endemic serogroup W135 meningococcal disease associated with a high mortality rate in South Africa. Clin Infect Dis. 2008;46:377\u201386.","journal-title":"Clin Infect Dis"},{"key":"196_CR5","unstructured":"Centers for Disease Control and Prevention. Meningococcal disease. Available at: http:\/\/www.cdc.gov\/vaccines\/pubs\/pinkbook\/downloads\/mening.pdf . Accessed March 23, 2017."},{"key":"196_CR6","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1056\/NEJMp048246","volume":"351","author":"MN Swartz","year":"2004","unstructured":"Swartz MN. Bacterial meningitis\u2014a view of the past 90\u00a0years. N Engl J Med. 2004;351:1826\u20138.","journal-title":"N Engl J Med"},{"issue":"suppl 2","key":"196_CR7","doi-asserted-by":"publisher","first-page":"B3","DOI":"10.1016\/j.vaccine.2011.12.062","volume":"30","author":"D Pace","year":"2012","unstructured":"Pace D, Pollard AJ. Meningococcal disease: clinical presentation and sequelae. Vaccine. 2012;30(suppl 2):B3\u20139.","journal-title":"Vaccine"},{"key":"196_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1478-7954-11-17","volume":"11","author":"RZ Jafri","year":"2013","unstructured":"Jafri RZ, Ali A, Messonnier NE, et al. Global epidemiology of invasive meningococcal disease. Popul Health Metr. 2013;11:11\u20137.","journal-title":"Popul Health Metr"},{"key":"196_CR9","first-page":"1","volume":"62","author":"AC Cohn","year":"2013","unstructured":"Cohn AC, MacNeil JR, Clark TA, et al. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013;62:1\u201328.","journal-title":"MMWR Recomm Rep"},{"key":"196_CR10","unstructured":"European Medicines Agency. Annex 1: summary of product characteristics (Nimenrix). Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002226\/WC500127663.pdf , 2017. Accessed March 9, 2018."},{"key":"196_CR11","doi-asserted-by":"publisher","first-page":"6529","DOI":"10.1016\/j.vaccine.2015.10.055","volume":"33","author":"MA Safadi","year":"2015","unstructured":"Safadi MA, O\u2019Ryan M, Valenzuela Bravo MT, et al. The current situation of meningococcal disease in Latin America and updated Global Meningococcal Initiative (GMI) recommendations. Vaccine. 2015;33:6529\u201336.","journal-title":"Vaccine"},{"key":"196_CR12","first-page":"129","volume":"88","author":"World Health Organization","year":"2013","unstructured":"World Health Organization. Meningococcal disease in countries of the African meningitis belt, 2012-emerging needs and future perspectives. Wkly Epidemiol Rec. 2013;88:129\u201336.","journal-title":"Wkly Epidemiol Rec"},{"key":"196_CR13","unstructured":"World Health Organization. Control of epidemic meningococcal disease. WHO practical guidelines. 2nd edition. Available at: http:\/\/www.who.int\/csr\/resources\/publications\/meningitis\/whoemcbac983.pdf . Accessed November 2, 2017."},{"key":"196_CR14","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1377\/hlthaff.2011.0328","volume":"30","author":"FM LaForce","year":"2011","unstructured":"LaForce FM, Okwo-Bele J-M. Eliminating epidemic group A meningococcal meningitis in Africa through a new vaccine. Health Aff (Millwood). 2011;30:1049\u201357.","journal-title":"Health Aff (Millwood)"},{"key":"196_CR15","unstructured":"MenAfriVac (meningococcal A conjugate vaccine). Full prescribing information, Serum Institute of India, Pune, India, 2015."},{"issue":"suppl 2","key":"196_CR16","doi-asserted-by":"publisher","first-page":"B40","DOI":"10.1016\/j.vaccine.2011.12.073","volume":"30","author":"MH Djingarey","year":"2012","unstructured":"Djingarey MH, Barry R, Bonkoungou M, et al. Effectively introducing a new meningococcal A conjugate vaccine in Africa: the Burkina Faso experience. Vaccine. 2012;30(suppl 2):B40\u20135.","journal-title":"Vaccine"},{"key":"196_CR17","unstructured":"World Health Organization. Meningitis weekly bulletin, inter country support team\u2014West Africa. Available at: http:\/\/www.meningvax.org\/epidemic-updates.php . Accessed August 31, 2016."},{"issue":"suppl 5","key":"196_CR18","doi-asserted-by":"publisher","first-page":"S410","DOI":"10.1093\/cid\/civ597","volume":"61","author":"C Lingani","year":"2015","unstructured":"Lingani C, Bergeron-Caron C, Stuart JM, et al. Meningococcal meningitis surveillance in the African meningitis belt, 2004-2013. Clin Infect Dis. 2015;61(suppl 5):S410\u20135.","journal-title":"Clin Infect Dis"},{"key":"196_CR19","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.15585\/mmwr.mm6649a3","volume":"66","author":"C Nnadi","year":"2017","unstructured":"Nnadi C, Oladejo J, Yennan S, et al. Large outbreak of Neisseria meningitidis Serogroup C\u2014Nigeria, December 2016\u2013June 2017. Morb Mortal Wkly Rep. 2017;66:1352\u20136.","journal-title":"Morb Mortal Wkly Rep"},{"key":"196_CR20","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ijid.2014.09.005","volume":"28","author":"ZA Memish","year":"2014","unstructured":"Memish ZA, Yezli S, Almasri M, et al. Meningococcal serogroup A, C, W, and Y serum bactericidal antibody profiles in Hajj pilgrims. Int J Infect Dis. 2014;28:171\u20135.","journal-title":"Int J Infect Dis."},{"key":"196_CR21","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ijid.2015.12.010","volume":"47","author":"S Yezli","year":"2016","unstructured":"Yezli S, Bin Saeed AA, Assiri AM, et al. Prevention of meningococcal disease during the Hajj and Umrah mass gatherings: past and current measures and future prospects. Int J Infect Dis. 2016;47:71\u20138.","journal-title":"Int J Infect Dis"},{"key":"196_CR22","first-page":"14","volume":"25","author":"S Parker","year":"2010","unstructured":"Parker S. The Hajj: a constant travel destination amidst changing times. S Afr J Epidemiol Infect. 2010;25:14\u20138.","journal-title":"S Afr J Epidemiol Infect"},{"key":"196_CR23","doi-asserted-by":"publisher","first-page":"665","DOI":"10.3201\/eid0906.020565","volume":"9","author":"JR Lingappa","year":"2003","unstructured":"Lingappa JR, Al-Rabeah AM, Hajjeh R, et al. Serogroup W-135 meningococcal disease during the Hajj, 2000. Emerg Infect Dis. 2003;9:665\u201371.","journal-title":"Emerg Infect Dis"},{"key":"196_CR24","first-page":"1410","volume":"25","author":"YY Al-Mazrou","year":"2004","unstructured":"Al-Mazrou YY, Al-Jeffri MH, Abdalla MN, Elgizouli SA, Mishskas AA. Changes in epidemiological pattern of meningococcal disease in Saudi Arabia. Does it constitute a new challenge for prevention and control? Saudi Med J. 2004;25:1410\u20133.","journal-title":"Saudi Med J"},{"key":"196_CR25","doi-asserted-by":"publisher","first-page":"e574","DOI":"10.1016\/j.ijid.2012.03.011","volume":"16","author":"M Ceyhan","year":"2012","unstructured":"Ceyhan M, Anis S, Htun-Myint L, et al. Meningococcal disease in the Middle East and North Africa: an important public health consideration that requires further attention. Int J Infect Dis. 2012;16:e574\u201382.","journal-title":"Int J Infect Dis"},{"key":"196_CR26","unstructured":"European Centre for Disease Prevention and Control. Invasive meningococcal disease. Available at: https:\/\/ecdc.europa.eu\/en\/publications-data\/invasive-meningococcal-disease-annual-epidemiological-report-2015 . Accessed February 13, 2018."},{"key":"196_CR27","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1093\/cid\/ciu881","volume":"60","author":"SN Ladhani","year":"2015","unstructured":"Ladhani SN, Beebeejaun K, Lucidarme J, et al. Increase in endemic Neisseria meningitidis capsular group W sequence type 11 complex associated with severe invasive disease in England and Wales. Clin Infect Dis. 2015;60:578\u201385.","journal-title":"Clin Infect Dis"},{"key":"196_CR28","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2016.21.12.30176","author":"P Stefanelli","year":"2016","unstructured":"Stefanelli P, Miglietta A, Pezzotti P, et al. Increased incidence of invasive meningococcal disease of serogroup C, clonal complex 11, Tuscany, Italy, 2015 to 2016. Euro Surveill. 2016;21(12). https:\/\/doi.org\/10.2807\/1560-7917.ES.2016.21.12.30176 .","journal-title":"Euro Surveill"},{"key":"196_CR29","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1017\/S0950268814001149","volume":"142","author":"R Abad","year":"2014","unstructured":"Abad R, Lopez EL, Debbag R, Vazquez JA. Serogroup W meningococcal disease: global spread and current affect on the Southern Cone in Latin America. Epidemiol Infect. 2014;142:2461\u201370.","journal-title":"Epidemiol Infect"},{"key":"196_CR30","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.jiph.2015.01.009","volume":"8","author":"EH Husain","year":"2015","unstructured":"Husain EH, Barakat M, Al-Saleh M. Trends and variations in the epidemiology of meningococcal disease in Kuwait 1987-2013. J Infect Public Health. 2015;8:441\u20137.","journal-title":"J Infect Public Health"},{"key":"196_CR31","unstructured":"Australian Government Department of Health. Invasive meningococcal disease national surveillance report. Available at: https:\/\/www.health.gov.au\/internet\/main\/publishing.nsf\/Content\/5FEABC4B495BDEC1CA25807D001327FA\/$File\/19-June-2017-IMD-Surveillance-report.pdf . Accessed November 2, 2017."},{"key":"196_CR32","volume-title":"Australian meningococcal surveillance programme annual report, 2015","author":"Australian Government Department of Health","year":"2016","unstructured":"Australian Government Department of Health. Australian meningococcal surveillance programme annual report, 2015, vol. 40. Australia: Canberra ACT; 2016."},{"key":"196_CR33","unstructured":"New Zealand Ministry of Health. The epidemiology of meningococcal disease in New Zealand. Available at: https:\/\/surv.esr.cri.nz\/PDF_surveillance\/MeningococcalDisease\/2013\/2013AnnualRpt.pdf . Accessed November 2, 2017."},{"key":"196_CR34","unstructured":"Public Health Agency of Canada. Invasive meningococcal disease. Available at: http:\/\/www.phac-aspc.gc.ca\/im\/vpd-mev\/meningococcal\/professionals-professionnels-eng.php . Accessed November 2, 2017."},{"key":"196_CR35","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1021\/acschembio.5b00758","volume":"11","author":"J Zhao","year":"2016","unstructured":"Zhao J, Nelson TJ, Vu Q, Truong T, Stains CI. Self-Assembling NanoLuc luciferase fragments as probes for protein aggregation in living cells. ACS Chem Biol. 2016;11:132\u20138.","journal-title":"ACS Chem Biol"},{"key":"196_CR36","unstructured":"Centers for Disease Control and Prevention. Enhanced meningococcal disease surveillance report. Atlanta: GA; 2016."},{"key":"196_CR37","unstructured":"International Association for Medical Assistance to Travelers. World Immunization Chart. Available at: https:\/\/www.iamat.org\/elibrary\/view\/id\/1359 . Accessed March 9, 2018."},{"key":"196_CR38","doi-asserted-by":"publisher","first-page":"177","DOI":"10.4155\/cli.11.165","volume":"2","author":"L Silva da","year":"2012","unstructured":"da Silva L, deTora L, Malerczyk C, Memish Z. Emergence of Neisseria meningitidis W-135 in the context of other rare serogroups. Clin Invest. 2012;2:177\u201388.","journal-title":"Clin Invest."},{"key":"196_CR39","unstructured":"Public Health England. Meningococcal disease: laboratory confirmed cases in England and Wales; invasive meningococcal C infections by epidemiological year and age group, England (1998 and 1999\u20132014 and 2015). Available at: https:\/\/www.gov.uk\/government\/publications\/meningococcal-disease-laboratory-confirmed-cases-in-england-and-wales . Accessed November 2, 2017."},{"key":"196_CR40","doi-asserted-by":"publisher","first-page":"30175","DOI":"10.2807\/1560-7917.ES.2016.21.12.30175","volume":"21","author":"H Campbell","year":"2016","unstructured":"Campbell H, Parikh SR, Borrow R, et al. Presentation with gastrointestinal symptoms and high case fatality associated with group W meningococcal disease (MenW) in teenagers, England, July 2015 to January 2016. Euro Surveill. 2016;21:30175.","journal-title":"Euro Surveill"},{"key":"196_CR41","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.jinf.2015.07.007","volume":"71","author":"J Lucidarme","year":"2015","unstructured":"Lucidarme J, Hill DM, Bratcher HB, et al. Genomic resolution of an aggressive, widespread, diverse and expanding meningococcal serogroup B, C and W lineage. J Infect. 2015;71:544\u201352.","journal-title":"J Infect"},{"key":"196_CR42","doi-asserted-by":"publisher","first-page":"e553","DOI":"10.1016\/j.ijid.2009.08.013","volume":"14","author":"JE Mueller","year":"2010","unstructured":"Mueller JE, Gessner BD. A hypothetical explanatory model for meningococcal meningitis in the African meningitis belt. Int J Infect Dis. 2010;14:e553\u20139.","journal-title":"Int J Infect Dis"},{"key":"196_CR43","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.3201\/eid1909.130077","volume":"19","author":"MJ Hossain","year":"2013","unstructured":"Hossain MJ, Roca A, Mackenzie GA, et al. Serogroup W135 meningococcal disease, The Gambia, 2012. Emerg Infect Dis. 2013;19:1507\u201310.","journal-title":"Emerg Infect Dis"},{"key":"196_CR44","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.3201\/eid2210.151935","volume":"22","author":"KS Carville","year":"2016","unstructured":"Carville KS, Stevens K, Sohail A, et al. Increase in meningococcal serogroup W disease, Victoria, Australia, 2013\u20132015. Emerg Infect Dis. 2016;22:1785\u20137.","journal-title":"Emerg Infect Dis"},{"key":"196_CR45","doi-asserted-by":"crossref","unstructured":"Tsang RSW, Deeks SL, Wong K, Marchand-Austin A, Jamieson FB. Invasive serogroup W Neisseria meningitidis (MenW) in Ontario, Canada shows potential clonal replacement during the period January 1, 2009 to June 30, 2016. Available at: http:\/\/www.phac-aspc.gc.ca\/publicat\/ccdr-rmtc\/16vol42\/dr-rm42-12\/ar-06-eng.php . Accessed March 27, 2017.","DOI":"10.14745\/ccdr.v42i12a06f"},{"key":"196_CR46","unstructured":"Tsang R, Hoang LM, Tyrrell GJ, et al. Increase in Neisseria meningitidis serogroup W invasive disease in Canada: 2009\u20132016. Available at: https:\/\/www.canada.ca\/en\/public-health\/services\/reports-publications\/canada-communicable-disease-report-ccdr\/monthly-issue\/2017-43\/ccdr-volume-43-7-8-July-6-2017\/increase-neisseria-meningitidis-serogroup-w-invasive-disease-canada-2009-2016.html . Accessed February 14, 2018."},{"key":"196_CR47","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3201\/eid1601.091026","volume":"16","author":"TJ Doyle","year":"2010","unstructured":"Doyle TJ, Mejia-Echeverry A, Fiorella P, et al. Cluster of serogroup W135 meningococci, southeastern Florida, 2008\u20132009. Emerg Infect Dis. 2010;16:113\u20135.","journal-title":"Emerg Infect Dis"},{"key":"196_CR48","first-page":"1","volume":"62","author":"AC Cohn","year":"2013","unstructured":"Cohn AC, MacNeil JR, Clark TA, et al. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013;62:1\u201328.","journal-title":"MMWR Recomm Rep"},{"key":"196_CR49","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1179\/2047773214Y.0000000126","volume":"108","author":"A Ali","year":"2014","unstructured":"Ali A, Jafri RZ, Messonnier N, et al. Global practices of meningococcal vaccine use and impact on invasive disease. Pathog Glob Health. 2014;108:11\u201320.","journal-title":"Pathog Glob Health"},{"key":"196_CR50","unstructured":"Nimenrix\u00ae: EPAR\u2014product information. European Medicines Agency. Available at: http:\/\/www.ema.europa.eu . Accessed July 28, 2017."},{"key":"196_CR51","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S0140-6736(83)90340-9","volume":"2","author":"J Finne","year":"1983","unstructured":"Finne J, Leinonen M, Makela PH. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet. 1983;2:355\u20137.","journal-title":"Lancet"},{"key":"196_CR52","unstructured":"Trumenba\u00ae (meningococcal group B vaccine). Full Prescribing Information, Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc, Philadelphia, PA, 2016."},{"key":"196_CR53","first-page":"608","volume":"64","author":"T Folaranmi","year":"2015","unstructured":"Folaranmi T, Rubin L, Martin SW, Patel M, MacNeil JR. Use of serogroup B meningococcal vaccines in persons aged \u2265\u200910\u00a0years at increased risk for serogroup B meningococcal disease: recommendations of the advisory committee on immunization practices, 2015. Morb Mortal Wkly Rep. 2015;64:608\u201312.","journal-title":"Morb Mortal Wkly Rep"},{"key":"196_CR54","unstructured":"European Medicines Agency. Committee for medicinal products for human use, summary of opinion: Trumenba. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Summary_of_opinion_-_Initial_authorisation\/human\/004051\/WC500224394.pdf . Accessed March 9, 2018."},{"key":"196_CR55","unstructured":"Pfizer Canada. Trumenba, Product Monograph. Available at: http:\/\/www.pfizer.ca\/sites\/g\/files\/g10037206\/f\/201711\/Trumenba_PM_195550_05-Oct-2017_E.pdf . Accessed March 9, 2018."},{"key":"196_CR56","unstructured":"Australian Government Department of Health. Prescription medicines: registration of new chemical entities in Australia. Available at: https:\/\/www.tga.gov.au\/prescription-medicines-registration-new-chemical-entities-australia . Accessed March 9, 2018."},{"key":"196_CR57","unstructured":"Bexsero\u00ae (meningococcal group B vaccine). Full prescribing information, Novartis, Cambridge, 2016."},{"key":"196_CR58","unstructured":"Bexsero\u00ae. Summary of product characteristics. Siena, Italy: Novartis; 2013."},{"key":"196_CR59","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1179\/2047773214Y.0000000162","volume":"108","author":"G Vernikos","year":"2014","unstructured":"Vernikos G, Medini D. Bexsero\u00ae chronicle. Pathog Glob Health. 2014;108:305\u201316.","journal-title":"Pathog Glob Health"},{"key":"196_CR60","unstructured":"European Medicines Agency. Bexsero. Available at: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/002333\/human_med_001614.jsp . Accessed June 9, 2016."},{"key":"196_CR61","volume-title":"The Australian immunisation handbook","author":"Australian Government Department of Health","year":"2015","unstructured":"Australian Government Department of Health. The Australian immunisation handbook. 10th ed. Canberra: Australian Technical Advisory Group on Immunisation; 2015.","edition":"10"},{"key":"196_CR62","unstructured":"Recommended schedule for the Expanded Program on Immunization, Bahrain. Kingdom of Bahrain Ministry of Health. Available at: https:\/\/www.moh.gov.bh\/HealthInfo\/Immunizations?lang=en . Accessed July 28, 2017."},{"key":"196_CR63","unstructured":"Government of Canada. Canadian immunization guide. Part 4. Active vaccines. Available at: https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/healthy-living\/canadian-immunization-guide-part-4-active-vaccines.html . Accessed May 2, 2017."},{"key":"196_CR64","unstructured":"Ministry of Health Saudi Arabia. Health requirements for travellers to Saudi Arabia for pilgrimage to Makkah (2016\/1437H Hajj) Available at: http:\/\/www.moh.gov.sa\/en\/Hajj\/Pages\/HealthRegulations.aspx . Accessed November 2, 2017."},{"key":"196_CR65","volume-title":"Meningococcal. The green book","author":"Public Health England","year":"2015","unstructured":"Public Health England. Meningococcal. The green book. London: Public Health England; 2015."},{"key":"196_CR66","unstructured":"MacNeil J, Meyer S. Meningococcal disease. Centers for Disease Control and Prevention. CDC health information for international travel 2016. New York: Oxford University Press; 2016."},{"key":"196_CR67","unstructured":"Public Health England. Meningococcal: The green book, Chapter 22. Available at: https:\/\/www.gov.uk\/government\/publications\/meningococcal-the-green-book-chapter-22 . Accessed November 2, 2017."},{"key":"196_CR68","unstructured":"World Health Organization. Standardization and validation of serological assays for the evaluation of immune responses to Neisseria meningitidis serogroup A\/C vaccines. Geneva, 8-9 March 1999. Available at: http:\/\/apps.who.int\/iris\/bitstream\/10665\/66298\/1\/WHO_V%26B_99.19.pdf . Accessed April 4, 2016."},{"key":"196_CR69","unstructured":"Malaysian Society of Infectious Diseases and Chemotherapy. Guidelines for adult immunisation. 2nd edition. Available at: http:\/\/docplayer.net\/14756999-Malaysian-society-of-infectious-diseases-and-chemotherapy-guidelines-for-adult-immunisation-2nd-edition.html . Accessed November 2, 2017."},{"key":"196_CR70","unstructured":"Saudia Arabia Ministry of Health. Meningococcal meningitis. Available at: https:\/\/www.moh.gov.sa\/en\/Hajj\/HealthGuidelines\/HealthGuidelinesDuringHajj\/Pages\/MeningococcalMeningitis.aspx . Accessed November 2, 2017."},{"key":"196_CR71","unstructured":"NIMENRIX (meningococcal polysaccharide serogroups A, C, W-135 and Y conjugate vaccine). Summary of product characteristics, Pfizer Ltd, Sandwich, Kent, 2017."},{"key":"196_CR72","doi-asserted-by":"publisher","unstructured":"Bethea J, Makki S, Gray S, MacGregor V, Ladhani S. Clinical characteristics and public health management of invasive meningococcal group W disease in the East Midlands region of England, United Kingdom 2011 to 2013. Euro Surveill. 2016;21(24). https:\/\/doi.org\/10.2807\/1560-7917.ES.2016.21.24.30259 .","DOI":"10.2807\/1560-7917.ES.2016.21.24.30259"},{"key":"196_CR73","unstructured":"NIMENRIX (Meningococcal polysaccharide serogroups A, C, W-135 and Y conjugate vaccine). Full prescribing information, Pfizer Australia Pty Ltd, West Ryde NSW, Australia, 2016."},{"key":"196_CR74","unstructured":"European Medicines Agency. Summary of Opinion (Menveo\u00ae). Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Summary_of_opinion_-_Initial_authorisation\/human\/001095\/WC500073647.pdf . Accessed November 2, 2017."},{"key":"196_CR75","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.4161\/hv.22166","volume":"8","author":"T Vesikari","year":"2012","unstructured":"Vesikari T, Forsten A, Boutriau D, et al. Randomized trial to assess the immunogenicity, safety and antibody persistence up to 3\u00a0years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers. Hum Vaccin Immunother. 2012;8:1892\u2013903.","journal-title":"Hum Vaccin Immunother"},{"key":"196_CR76","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1097\/INF.0b013e31828693c5","volume":"32","author":"NP Klein","year":"2013","unstructured":"Klein NP, Baine Y, Bianco V, et al. One or two doses of quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine is immunogenic in 9- to 12-month-old children. Pediatr Infect Dis J. 2013;32:760\u20137.","journal-title":"Pediatr Infect Dis J."},{"key":"196_CR77","unstructured":"Nimenrix\u00ae, Summary of Product Characteristics (Meningococcal group A, C, W-135 and Y conjugate vaccine). Full prescribing information, Pfizer Ltd, Sandwich, Kent, 2018."},{"key":"196_CR78","unstructured":"Nimenrix\u00ae, Product information (Meningococcal polysaccharide serogroups A, C, W-135 and Y conjugate vaccine). Full prescribing information, Pfizer Australia Pty Ltd, West Ryde NSW, 2016."},{"key":"196_CR79","unstructured":"Nimenrix Product Monograph (Meningococcal polysaccharide groups A, C, W-135 and Y conjugate vaccine). Full Prescribing information, Pfizer Canada Inc, Kirkland, 2016."},{"key":"196_CR80","unstructured":"Menveo\u00ae Summary of Product Characteristics (Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine). Full Prescribing Information, GSK Vaccines, Srl, Via Fiorentia, Italy, 2017."},{"key":"196_CR81","unstructured":"Menveo\u00ae (Meningococcal (Groups A, C, Y and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine). Full Prescribing Information, Novartis Vaccines and Diagnostics, Inc., Cambridge, MA, USA, 2013."},{"key":"196_CR82","unstructured":"Menveo\u00ae Product Information (Meningococcal (Groups A, C, W-135 and Y) Oligosaccharide CRM197 Conjugate Vaccine). Full prescribing information, GlaxoSmithKline Australia Pty Ltd, Abbotsford, Victoria, 2017."},{"key":"196_CR83","unstructured":"Menveo\u00ae Product Monograph (Meningococcal (Groups A, C, W-135 and Y) Oligosaccharide CRM197 Conjugate Vaccine). Full prescribing information, GlaxoSmithKline Inc., Mississauga, Ontario, 2017."},{"key":"196_CR84","unstructured":"Menactra\u00ae (MCV4). Full prescribing information, Sanofi Pasteur, 2011."},{"key":"196_CR85","unstructured":"Menactra\u00ae Australian Product Information (Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine). Full prescribing information, Sanofi-Aventis Australia Pty Ltd, Macquarie Park, NSW, 2014."},{"key":"196_CR86","unstructured":"Health requirements for travellers to Saudi Arabia for pilgrimage to Makkah (2017\/1438 Hajj). Saudi Arabia Ministry of Health. Available at: http:\/\/www.moh.gov.sa\/en\/Hajj\/Pages\/HealthRegulations.aspx . Accessed July 28, 2017."}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-018-0196-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40121-018-0196-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-018-0196-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,12]],"date-time":"2019-10-12T21:45:05Z","timestamp":1570916705000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40121-018-0196-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,17]]},"references-count":86,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["196"],"URL":"https:\/\/doi.org\/10.1007\/s40121-018-0196-z","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,17]]},"assertion":[{"value":"6 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2018","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}